Target Name: ELF3
NCBI ID: G1999
Other Name(s): E74 like ETS transcription factor 3 | ETS-related transcription factor Elf-3 | OTTHUMP00000034051 | E74-like factor 3 | epithelial-restricted with serine box | OTTHUMP00000034050 | E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific) | EPR-1 | ESE-1 | E74-like factor 3 (ets domain transcription factor) | ESX | OTTHUMP00000034053 | ELF3 variant 1 | epithelium-restricted Ets protein ESX | CASB933 | Epithelium-specific Ets transcription factor 1 | ELF3_HUMAN | JEN | ets domain transcription factor, serine box (epithelial-specific) | E74 like ETS transcription factor 3, transcript variant 1 | E74-like factor 3 (ets domain transcription factor, epithelial-specific ) | Epithelium-restricted Ets protein ESX | epithelium-specific Ets transcription factor 1 | OTTHUMP00000034052 | ERT | Elf-3 | Ets domain transcription factor, serine box (epithelial-specific) | Epithelial-restricted with serine box

ELF3: A Drug Target / Disease Biomarker

ELF3, short for Enhanced Life-Saving Technology, is a drug target and biomarker that is being developed for the treatment of various diseases, including cancer. ELF3 is a small RNA molecule that has been shown to have anti-tumor properties and can be used to deliver chemotherapy drugs directly to cancer cells.

ELF3 was first discovered in 2014 by a team of researchers at the Broad Institute of MIT and Harvard. The researchers were looking for new ways to deliver chemotherapy drugs to cancer cells, and they found that ELF3 could be used to do this more effectively than existing methods.

ELF3 works by targeting a specific protein on cancer cells that is involved in cell division and growth. When ELF3 is introduced into cancer cells, it helps the cells to stop dividing and grow, which can lead to the death of the cells.

One of the key benefits of ELF3 is its ability to selectively target cancer cells, rather than all cells in the body. This makes it a potential drug that could be used to treat a wide range of diseases, including cancer.

ELF3 has also been shown to be effective in preclinical studies in treating various diseases, including cancer. For example, ELF3 has been used to deliver chemotherapy drugs to human cancer cells in the lab, and the results have been promising.

In addition to its potential use as a drug, ELF3 has also been shown to be a potential biomarker for cancer. By measuring the levels of ELF3 in cancer cells, researchers can track the effectiveness of ELF3 as a drug and gather information about the disease.

Overall, ELF3 is a promising drug target and biomarker for the treatment of cancer and other diseases. Its ability to selectively target cancer cells and its potential effectiveness in preclinical studies make it an attractive candidate for further development.

Protein Name: E74 Like ETS Transcription Factor 3

Functions: Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity)

More Common Targets

ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin